Recombinetics Announces Collaboration with Mayo Clinic to Develop the First-Ever Swine Models of Osteogenesis Imperfecta Read More
Recombinetics Awarded National Institutes of Health Funding to Develop Genetically Engineered Swine Model of Glioblastoma, the Deadliest Type of Brain Tumor Read More
Recombinetics Names Dr. Tad Sonstegard the First Chief Executive Officer of Its Wholly-Owned Subsidiary, Acceligen Read More
Medical Alley Q3 Breakdown: All Major Sectors in Medical Alley Break $100 Million Raised for First Time Read More
Recombinetics Announces Collaboration with Mayo Clinic to Grow Human Cardiomyocytes in Swine for Exo-transplantation Read More
Recombinetics Launches TARGET-TB with Researchers in the Republic of Ireland and Northern Ireland to Develop Genome Editing Solutions for Bovine Tuberculosis Read More
Recombinetics Announces New Board of Directors with Representatives from a Series A Strategic Investor: Gundersen Health System Read More
